- Home
- ALXO vs CLSD Comparison
ALXO vs CLSD Comparison
Compare ALXO & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- CLSD
- Stock Information
- Founded
- ALXO 2015
- CLSD 2011
- Country
- ALXO United States
- CLSD United States
- Employees
- ALXO N/A
- CLSD N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- ALXO Health Care
- CLSD Health Care
- Exchange
- ALXO Nasdaq
- CLSD Nasdaq
- Market Cap
- ALXO 58.9M
- CLSD 68.4M
- IPO Year
- ALXO 2020
- CLSD 2016
- Fundamental
- Price
- ALXO $1.06
- CLSD $0.32
- Analyst Decision
- ALXO Strong Buy
- CLSD Hold
- Analyst Count
- ALXO 6
- CLSD 4
- Target Price
- ALXO $3.30
- CLSD $4.33
- AVG Volume (30 Days)
- ALXO 1.7M
- CLSD 670.5K
- Earning Date
- ALXO 11-06-2025
- CLSD 11-11-2025
- Dividend Yield
- ALXO N/A
- CLSD N/A
- EPS Growth
- ALXO N/A
- CLSD N/A
- EPS
- ALXO N/A
- CLSD N/A
- Revenue
- ALXO N/A
- CLSD $4,166,000.00
- Revenue This Year
- ALXO N/A
- CLSD $98.20
- Revenue Next Year
- ALXO N/A
- CLSD $213.77
- P/E Ratio
- ALXO N/A
- CLSD N/A
- Revenue Growth
- ALXO N/A
- CLSD N/A
- 52 Week Low
- ALXO $0.40
- CLSD $0.29
- 52 Week High
- ALXO $2.36
- CLSD $1.65
- Technical
- Relative Strength Index (RSI)
- ALXO 54.74
- CLSD 32.43
- Support Level
- ALXO $1.06
- CLSD $0.31
- Resistance Level
- ALXO $1.27
- CLSD $0.36
- Average True Range (ATR)
- ALXO 0.12
- CLSD 0.03
- MACD
- ALXO -0.02
- CLSD 0.00
- Stochastic Oscillator
- ALXO 32.26
- CLSD 6.76
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.